SCHEMBL4044238

SCHEMBL4044238

N#Cc1cccc(C2(C(CCc3ccccc3)C(=O)NC3CCCCC3)Nc3ccccc3N2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.42
BACE1 P56817 1/20 0.42
BACE2 Q9Y5Z0 1/20 0.42
EPHX1 P07099 6/20 0.40
EPHX2 P34913 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 1/20 0.39
MMP2 P08253 2/20 0.39
HPGD P15428 1/20 0.39
MMP3 P08254 1/20 0.39
ACKR3 P25106 1/20 0.38
MCHR1 Q99705 1/20 0.38
CHRM3 P20309 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043336 0.87 OPRD1 (0.41) EPHX1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4037580 0.85 TSHR (0.40) CTSDBACE1BACE2EPHX1SMN1; SMN2
SCHEMBL4041615 0.85 CNR1 (0.41) BACE1TSHRALDH1A1
SCHEMBL4044228 0.85 TSHR (0.41) CTSDBACE1BACE2EPHX1SMN1; SMN2
SCHEMBL4035090 0.80 ALDH1A1 (0.43) EPHX1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4036682 0.75 METAP2 (0.44) CTSDALDH1A1HTTMMP2HPGD
SCHEMBL4038935 0.75 METAP2 (0.43) CTSDSMN1; SMN2TSHRALDH1A1HTT
SCHEMBL4040042 0.74 MEN1 (0.46) CTSDEPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4036794 0.74 EPHX2 (0.44) EPHX1EPHX2SMN1; SMN2NPC1RAB9A
SCHEMBL4034837 0.74 NPC1 (0.48) EPHX1EPHX2SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed